Home/Filings/4/0000950170-24-042381
4//SEC Filing

Moran Kyle 4

Accession 0000950170-24-042381

CIK 0001631574other

Filed

Apr 4, 8:00 PM ET

Accepted

Apr 5, 8:00 PM ET

Size

5.6 KB

Accession

0000950170-24-042381

Insider Transaction Report

Form 4
Period: 2024-04-03
Moran Kyle
Chief Financial Officer
Transactions
  • Sale

    Ordinary Shares

    2024-04-03$6.17/sh15,630$96,42133,921 total
Footnotes (3)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023.
  • [F2]The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $6.115 to $6.23 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  • [F3]Includes 3,431 ordinary shares acquired on January 14, 2024, under the issuer's 2019 Employee Share Purchase Plan.

Documents

1 file

Issuer

Wave Life Sciences Ltd.

CIK 0001631574

Entity typeother

Related Parties

1
  • filerCIK 0001657765

Filing Metadata

Form type
4
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 8:00 PM ET
Size
5.6 KB